[The seroprevalence of HCV among injecting drug users in the years 2004-2008 in Slovakia].

Vnitr Lek

Fakulta Asetrovatel'stva a Zdravotníckych Stúdií Slovenskej Univerzity, Slovenská Republika, Rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc.

Published: March 2012

Introduction: Virus of hepatitis C (HCV) is the leading cause of chronic liver disease, including cirrhosis and cancer, and the most common indication for liver transplantation. In industrialised countries, injecting drug use is currently the most important risk factor for infection with hepatitis C, resulting in high prevalence of hepatitis C among injecting drug users (IDUs). The aim of the study was to assess the seroprevalence of HCV infection and distribution of genotypes among IDUs in the years 2004-2008.

Probands And Methods: A total number of 846 probands, both sexes (590 males and 256 females) with mean age from 24 to 29 years were investigated in the years 2004-2008. Standard virological tests were performed.

Results: The seroprevalence of anti-HCV positivity during the years 2004-2008 were in range 34-78% and positivity of HCV RNA assessed by PCR method were in range 17-71%. The genotypes distribution was in favour of genotype 3.

Conclusions: In Slovakia IDUs represent risk group with high prevalence of hepatitis C. These results are comparable to those published in other European countries.

Download full-text PDF

Source

Publication Analysis

Top Keywords

injecting drug
12
years 2004-2008
12
seroprevalence hcv
8
drug users
8
high prevalence
8
prevalence hepatitis
8
years
5
[the seroprevalence
4
hcv
4
hcv injecting
4

Similar Publications

Proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has added a new paradigm to our understanding of cholesterol homeostasis and lipid metabolism. Since its discovery, PCSK9 inhibitors have become a widely investigated therapeutic class for lipid management in cardiovascular diseases and hypercholesterolemia. Scientists have explored different approaches for PCSK9 inhibition, such as monoclonal antibodies (mAbs), gene silencing and gene editing techniques, vaccines, mimetic peptides, and small molecules.

View Article and Find Full Text PDF

Growth-plate (GP) injures in limbs and other sites can impair GP function and cause deceleration of bone growth, leading to progressive bone lengthening imbalance, deformities and/or physical discomfort, decreased motion and pain. At present, surgical interventions are the only means available to correct these conditions by suppressing the GP activity in the unaffected limb and/or other bones in the ipsilateral region. Here, we aimed to develop a pharmacologic treatment of GP growth imbalance that involves local application of nanoparticles-based controlled release of a selective retinoic acid nuclear receptor gamma (RARγ) agonist drug.

View Article and Find Full Text PDF

Botulinum toxin injections, a popular aesthetic treatment, have over 7.4 million beneficiaries in the U.S.

View Article and Find Full Text PDF

Background: Treatment guidelines recommend metformin as initial drug in many people with type 2 diabetes (T2D) and low risk of cardiovascular disease, with the possibility to switch to or add other drug classes. A decision aid (DA) could be useful to incorporate a patient's preferences in the decision of which drug class to choose. We developed such a DA and assessed the perspectives of people with T2D towards its comprehensibility and usability.

View Article and Find Full Text PDF

Introduction: 7,8-Dihydroxyflavone (7,8-DHF) is a promising translational therapy in several brain injury models, including the neonatal hypoxia-ischemia (HI) model in mice. However, the neuroprotective effect of 7,8-DHF was only observed in female, but not male, neonatal mice with HI brain injury. It is unknown whether HI-induced physiological changes affect brain distribution of 7,8-DHF differently for male versus female mice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!